Mynvax
Mynvax is a clinical stage vaccine biotechnology company dedicated to developing novel, thermostable recombinant vaccines for respiratory viral infections, including COVID-19 and influenza. Founded in 2017 and supported by Indian and global investors, Mynvax leverages its scientific expertise and intellectual property to create improved vaccines that are accessible to low and middle-income countries. The company collaborates with research institutions and vaccine manufacturers to advance its innovative vaccine programs.
Industries
Nr. of Employees
small (1-50)
Products
Adjuvanted quadrivalent recombinant influenza subunit vaccine candidate (insect-cell manufactured)
A recombinant quadrivalent influenza vaccine formulation containing engineered hemagglutinin derivatives and adjuvant; manufactured in insect cells and designed for seasonal protection with formulations for northern and southern hemispheres.
Thermotolerant adjuvanted RBD-based SARS-CoV-2 protein subunit vaccine candidate (CHO-produced)
An engineered receptor-binding domain (RBD) protein subunit vaccine formulated with an adjuvant and designed to be thermotolerant for reduced cold-chain dependence; produced in CHO cell lines for scalability.
Adjuvanted quadrivalent recombinant influenza subunit vaccine candidate (insect-cell manufactured)
A recombinant quadrivalent influenza vaccine formulation containing engineered hemagglutinin derivatives and adjuvant; manufactured in insect cells and designed for seasonal protection with formulations for northern and southern hemispheres.
Thermotolerant adjuvanted RBD-based SARS-CoV-2 protein subunit vaccine candidate (CHO-produced)
An engineered receptor-binding domain (RBD) protein subunit vaccine formulated with an adjuvant and designed to be thermotolerant for reduced cold-chain dependence; produced in CHO cell lines for scalability.
Services
Preclinical vaccine development and animal testing
End-to-end preclinical development including antigen design, biophysical characterization, immunogenicity testing, and protective efficacy studies in multiple animal models.
Process development and antigen manufacturing
Upstream and downstream process development for recombinant vaccine antigens, small- to medium-scale bioreactor operation, purification (FPLC), and optimization for scale-up.
Technology transfer and manufacturing partnerships
Commercial development partnerships and technology transfer for manufacturing of protein components and vaccine candidates to contract manufacturers and large vaccine producers.
Intellectual property and patent analytics services
Patent filing coordination, licensing and in/out-licensing management, freedom-to-operate and patentability analyses to support R&D and commercialization.
Preclinical vaccine development and animal testing
End-to-end preclinical development including antigen design, biophysical characterization, immunogenicity testing, and protective efficacy studies in multiple animal models.
Process development and antigen manufacturing
Upstream and downstream process development for recombinant vaccine antigens, small- to medium-scale bioreactor operation, purification (FPLC), and optimization for scale-up.
Technology transfer and manufacturing partnerships
Commercial development partnerships and technology transfer for manufacturing of protein components and vaccine candidates to contract manufacturers and large vaccine producers.
Intellectual property and patent analytics services
Patent filing coordination, licensing and in/out-licensing management, freedom-to-operate and patentability analyses to support R&D and commercialization.
Expertise Areas
- Vaccine design and protein engineering
- Thermostable vaccine formulation
- Preclinical immunology and animal challenge studies
- Bioprocess and cell-line development
Key Technologies
- Structure-guided protein engineering
- Saturation mutagenesis and deep mutational scanning
- Surface-display screening libraries
- Mammalian, CHO, Pichia pastoris and insect cell expression systems